Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial

Fig. 1

Trial concept. Conventional diuretics are well established agents for CHF. On the other hand, SGLT2 inhibitors are new anti-diabetic agents with multiple favorable effects such as improving glycemic and metabolic parameters. In addition, empagliflozin has recently been reported to reduce the risk of CV events asterisk [13]. However, the beneficial effects of SGLT2 inhibitors in T2DM patients with CHF have yet to be established. BP blood pressure, BW body weight, CHF chronic heart failure, CV cardiovascular, SGLT2 sodium glucose cotransporter 2, T2DM type 2 diabetes mellitus

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840